Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) is projected to release its Q4 2026 results before the market opens on Wednesday, October 28th. Analysts expect Lexaria Bioscience to announce earnings of ($0.90) per share and revenue of $0.05 million for the quarter. Interested persons may visit the company’s upcoming Q4 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 24, 2026 at 12:00 AM ET.
Lexaria Bioscience Price Performance
Shares of NASDAQ LEXX opened at $3.08 on Monday. Lexaria Bioscience has a twelve month low of $2.43 and a twelve month high of $21.60. The business’s 50 day moving average price is $6.11 and its two-hundred day moving average price is $8.34. The company has a market cap of $6.50 million, a PE ratio of -0.60 and a beta of 0.61.
Wall Street Analyst Weigh In
Several research firms have commented on LEXX. Wall Street Zen upgraded shares of Lexaria Bioscience to a “sell” rating in a report on Saturday, October 10th. Weiss Ratings downgraded Lexaria Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $22.50.
Get Our Latest Analysis on LEXX
Lexaria Bioscience Company Profile
Lexaria Bioscience Corp. (NASDAQ:LEXX) is a biotechnology company developing drug-delivery technologies designed to improve the way active pharmaceutical and nutritional compounds are absorbed and used by the body. Its principal technology, DehydraTECH, is intended to enhance the delivery, bioavailability, and performance of orally administered compounds.
The company has investigated DehydraTECH applications involving cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, antiviral compounds, and other active ingredients.
Featured Articles
- Five stocks we like better than Lexaria Bioscience
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
